“Amgen (AMGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of A . The company’s strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
,” TheStreet’s analyst commented.
Shares of Amgen traded up 0.07% during mid-day trading on Tuesday, hitting $91.60. Amgen has a one year low of $65.37 and a one year high of $94.29. The stock’s 50-day moving average is currently $87.62. The company has a market cap of $68.556 billion and a P/E ratio of 16.58.
The company also recently declared a quarterly dividend, which is scheduled for Friday, June 7th. Shareholders of record on Thursday, May 16th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.05%. The ex-dividend date of this dividend is Tuesday, May 14th.
A number of other analysts have also recently weighed in on AMGN. Analysts at S&P Equity Research raised their price target on shares of Amgen from $100.00 to $104.00 in a research note to investors on Tuesday, February 26th. They now have a buy rating on the stock. Separately, analysts at Guggenheim raised their price target on shares of Amgen from $93.00 to $95.00 in a research note to investors on Tuesday, February 26th. They now have a neutral rating on the stock. Finally, analysts at Bank of America raised their price target on shares of Amgen to $99.00 in a research note to investors on Monday, February 25th.
Eleven equities research analysts have rated the stock with a buy rating, three have issued an overweight rating, and sixteen have given a hold rating to the stock. The company presently has a consensus rating of overweight and an average target price of $96.98.
Amgen Inc. (Amgen) is a biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for illnesses.
To view TheStreet’s full report, visit www.thestreetratings.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.